Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
Description: Combretastatin A4 (CA4) is a potent inhibitor of tubulin polymerization that displays strong inhibitory activity on tumor cell growth. Combretastatin-A-4-3'-O-Phosphate (CA4P) is a CA4 prodrug that inhibits tumor growth in several cell lines including P-388 (leukemia), SK-N-SH (neuroblast), BXPC-3 (pancreas), NCI-H460 (lung), and DU-145 (prostate) with ED50 values of 0.0029, 0.00025, 0.23, 0.00035, and 0.00072 ug/ml, respectively. CA4P specifically targets the tumor vasculature. In a rat model of carcinosarcoma, CA4P delivered intraperitoneally at a dose of 100 mg/kg effectively disrupts tumor blood flow within six hours after administration without significantly affecting normal tissues.
2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-phenol, dihydrogen phosphate, disodium salt
CA4P (sodium salt) is sparingly soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide. For biological experiments, we suggest that organic solvent-free aqueous solutions of CA4P (sodium salt) be prepared by directly dissolving the CA4P (sodium salt) compound in aqueous buffers. The solubility of CA4P (sodium salt) in PBS, pH 7.2, is approximately 5 mg/ml. We do not recommend storing the aqueous solution for more than one day.
Pettie, G.R., Rhodes, M.R., Herald, D.L., et al. Antineoplastic agents. 445. Synthesis and evaluation of structural modifications of (Z)- and (E)-combretastatin A4. J. Med. Chem. 48, 4087-4099 (2005).
Tozer, G.M., Prise, V.E., Wilson, J., et al. Combretastatin A4 phosphate as a tumor vascular-targeting agent: Early effects in tumors and normal tissues. Cancer Res. 59, 1626-1634 (1999).